Barclays Upgrades Thermo Fisher Scientific (NYSE:TMO) to "Overweight"

Key Points

• Barclays has upgraded Thermo Fisher Scientific from an "equal weight" to an "overweight" rating, increasing its price target from $490 to $550, suggesting a potential upside of 15.30%.
• In addition to Barclays, several other analysts have also raised their price targets, with Scotiabank setting a price objective of $590 and Raymond James adjusting its target to $535.
• Thermo Fisher reported earnings of $5.36 per share for the last quarter, exceeding analysts' expectations, and demonstrated a year-over-year revenue growth of 2.9%.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) was upgraded by stock analysts at Barclays from an "equal weight" rating to an "overweight" rating in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has a $550.00 target price on the medical research company's stock, up from their previous target price of $490.00. Barclays's price target would indicate a potential upside of 15.30% from the company's current price.

Several other equities analysts have also weighed in on the company. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a report on Friday, July 11th. Raymond James Financial reissued an "outperform" rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. William Blair assumed coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating for the company. UBS Group raised their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. Finally, Wall Street Zen lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday. Seventeen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average target price of $592.24.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $477.03 on Thursday. The firm has a market cap of $180.13 billion, a PE ratio of 27.59, a P/E/G ratio of 2.58 and a beta of 0.75. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The business has a 50 day moving average of $464.58 and a 200-day moving average of $452.37. Thermo Fisher Scientific has a 12-month low of $385.46 and a 12-month high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.Thermo Fisher Scientific's quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the company posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific will post 23.28 earnings per share for the current year.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 400 shares of the business's stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the transaction, the chief executive officer owned 113,762 shares in the company, valued at $56,937,881. The trade was a 0.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 over the last 90 days. Corporate insiders own 0.33% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of TMO. Bernard Wealth Management Corp. purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $25,000. CBIZ Investment Advisory Services LLC grew its holdings in shares of Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after acquiring an additional 33 shares during the period. Ameriflex Group Inc. purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $30,000. Anderson Financial Strategies LLC purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $30,000. Finally, Keystone Global Partners LLC purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $31,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.